Sosyal Güvenlik Kurumu (SGK) published a new announcement concerning health expenditures and prescription drug use that affects millions of citizens. In the institution’s statement dated 25 March 2026, it was reported that adjustments were made to the list of drugs for which costs will be reimbursed. After the announcement, attention turned to which drug groups the changes cover and how these updates will affect the process at pharmacies.
The SGK notice was issued under the title “Announcement Regarding Amendments to the List of Drugs Whose Costs Will Be Covered 2026/13.” Attached to the announcement were both PDF and Excel files. This indicates the update is more than a brief notice and includes technical, list-based changes. Therefore it is particularly important for people who use medication continuously, patients with medical reports, those who will soon have prescriptions written, and citizens who will obtain medicines from pharmacies to check the new list.
The most widely asked question remains whether this amendment will have a direct financial impact on citizens. In practice, changes to SGK reimbursement lists can have various consequences: some medicines may be added to coverage, payment conditions for certain products may be updated, or technical explanations may be revised. For citizens, the key issue is which conditions apply to their medication in the updated list. The supplementary files published by SGK are provided precisely so these details can be checked.
These updates are followed especially closely by people with chronic illnesses, because even small changes in reimbursement coverage can affect many stages from the prescription process to pharmacy delivery. Experts watching such announcements typically focus on a few consistent points: whether a medicine remains on the list, whether report requirements have changed, whether payment rules have been updated, and when the changes take effect. This announcement’s notable publication date is 25 March 2026, with 27 March 2026 highlighted as an important implementation threshold. These dates are consistent with SGK’s usual announcement practice.
The most prudent step for citizens is to verify the current SGK announcement and how pharmacies are applying it before starting a prescription or using a medication. Although not every list update impacts a wide population equally, significant effects can occur within specific drug groups. Notices like this are particularly important in practice for patients using medications under medical reports, children receiving treatment, retirees on regular therapy, and people covered by general health insurance.
SGK’s recent announcement indicates that social security and health spending will remain a key topic in the coming days. According to the official statement, the regulation was announced to the public as of today. Citizens should follow the details relevant to their own medications and prescription procedures via the additional lists. The practical impact of the new regulation will become clearer through pharmacy operations and prescription practices in the field.